The Comparison of Efficacy and Safety between Venetoclax Combined with Demethylating Drugs and the "3+7" Drug Regimen for Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.01.004
- Author:
Na CUI
1
;
Li-Jing WANG
2
;
Chang-Yong YUAN
2
Author Information
1. School of Clinical Medicine, Shandong Second Medical University, Weifang 261000, Shandong Province, China.
2. Department of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou 253000, Shandong Province, China.
- Publication Type:English Abstract
- Keywords:
acute myeloid leukemia;
elderly;
venetoclax;
demethylation;
safety;
strong chemotherapy
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Sulfonamides/therapeutic use*;
Bridged Bicyclo Compounds, Heterocyclic/administration & dosage*;
Retrospective Studies;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Female;
Male;
Decitabine/therapeutic use*;
Azacitidine/therapeutic use*;
Middle Aged;
Treatment Outcome;
Adult;
Aged;
Remission Induction
- From:
Journal of Experimental Hematology
2025;33(1):25-31
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the efficacy and safety of venetoclax combined with demethylating drugs and intense chemotherapy in the treatment of acute myeloid leukemia (AML).
METHODS:The clinical data of 76 patients with AML treated in Qilu Hospital of Shandong University Dezhou Hospital from January 2019 to March 2024 were retrospectively analyzed. Patients were divided into observation group and control group. 38 patients in the observation group received venetoclax combined with demethylating drugs (decitabine or azacytidine) and 38 patients in the control group with the "3+7" intensive chemotherapy regimen. The primary endpoints of clinical observation were complete remission (CR), CR with incomplete hematologic recovery (CRi), partial remission (PR), non remission (NR), and overall response rate (ORR). Secondary endpoints were overall survival (OS) and drug safety.
RESULTS:After 2 courses of treatment, the CR+CRi rate in observation group and control group was 71.05% and 65.79%, respectively, and the ORR was 81.58% and 78.95%, respectively. After all courses of treatment, CR+CRi rate in the observation group and the control group was 73.68% and 78.95%, respectively, and the ORR was 81.58% and 84.21%, respectively, with no statistical significance between the two groups (P >0.05). After 1 course of treatment, there were statistically significant differences in the proportion and degree of myelosuppression, the duration of neutropenia and the duration of thrombocytopenia between the two groups (P < 0.05), while there were no statistically significant differences in the occurrence of neutropenia with fever between the two groups (P >0.05). The incidence of non-hematological adverse reactions was highest in infection (mainly pulmonary infection) and gastrointestinal reaction. Among the many adverse reactions, there were statistically significant differences in the infection and hypokalemia between the two groups (P < 0.05), the incidence of hypokalemia in observation group and control group was 42.11% and 15.79%, respectively, and the infection rate in observation group and control group was 73.68% and 94.74%, respectively. The median OS was 13.13(1.67-53.63) months in the observation group and 16.60(0.57-59.67) months in the control group.
CONCLUSION:The combination of venetoclax and demethylating drugs has a low degree of myelosuppression, but a long recovery time, a response rate as good as that of intensive chemotherapy, and a lower infection rate. However, the incidence of hypokalemia is low in the intensive chemotherapy regimen, and the regimen significantly improves the long-term outcome of patients.
